Theratechnologies Inc T.TH

ADC targeting SORT1

[LouisW]

https://www.mdpi.com/1422-0067/24/24/17631

This china group is seemingly interested in SORT1, they pulished another paper to investigate the performace of mAb targeting Her2 and SORT1. I agree SORT1 is a highly potential target, question is whether TH1902 can reproduce the phenomena that Th observed in rodent in human.

[palinc2000]

extract from the study...re dosage  Previous studies had shown that SORT1 was overexpressed in breast cancer cells and underexpressed in normal cells [17]. Our results demonstrated that the surface of breast cancer cells was localized with a large amount of SORT1, while it was not present on the surface of non-tumor breast cell_MCF-10A. The expression profile supported SORT1 as a potential

[Mannequin]

But a PDC should be able to work its way in and release payload better than ADC. There's reasons they chose PDC. 

[palinc2000]

They did not chose PDC over ADC.They purchased Katana 5-6 years ago which had been trying to find a Buyer for more than a year and was not able to get a deal with any pharnas/biotechs involved in oncology...So THTX was apparently the only suitor .... no expertise in oncology .no corporate stucture to support going into R&D and no financial means to see this novel platform thru ....Of course at

[Trogarzon]

I always have Angiochem in the back of my mind.  They basically took a similar approach with soft cancers I think and failed.  

[Trogarzon]

Maybe Scarlett or some internal resource in disguise can tell us why Th1902 is better than a sortilin ADC now.